21.02.2021, 2312 Zeichen

Rosenbauer: In 2020, the Rosenbauer Group, world’s leading manufacturer of systems for firefighting and disaster
protection, successfully overcame the restrictions imposed by the COVID-19 pandemic and once again achieved a record year. Both revenues and EBIT reached historic highs of Euro 1,041.3 mn (2019: Euro 978.1 mn) and Euro 57.0 mn (2019: Euro 51.9 mn) respectively. The financial result was at the level of the previous year, with lower shares of joint ventures being offset by likewise lower interest expenses. Earnings before taxes (EBT) therefore amounted to Euro 50.5 mn (2019: Euro 45.5 mn). In the past year, the Rosenbauer Group reported solid incoming orders of Euro 1,007.7 mn (2019: Euro 1,073.0 mn). Orders in the CEEU (Central and Eastern Europe) and NOMA (North and Central America) sales regions in particular increased, as did the Stationary Fire Protection segment. In the US, for example, almost ten initial orders were received for the Revolutionary Technology (RT) – the first Rosenbauer firefighting vehicle with an alternative drive system. The MENA area was stable compared with 2019. At Euro 1,072.1 mn as of December 31, 2020 (2019: Euro 1,149.5 mn), the order backlog was on a par with consolidated annual revenue. Based on this solid order backlog, Rosenbauer’s Executive Board expects stable revenues and, once again, an EBIT margin in the region of 5% for 2021. Possible business disruptions due to the COVID-19 pandemic do not allow for a more precise forecast at this point in time.
Rosenbauer: weekly performance: 2.39%

Marinomed: Marinomed Biotech announces that a nasal spray with iota-carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. These were the results of an independent and investigator-initiated study conducted by an Argentinian research group. In the multicenter, randomized, double-blind, controlled CARR-COV-02 study, 394 healthcare staff were randomly assigned to receive iota-carrageenan nasal spray (N = 199) or placebo (N = 195) four times per day. Both groups had similar gender and age distributions.
Marinomed Biotech: weekly performance: 17.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (19/02/2021)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S12/08: Robert Abend

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.

---